Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 5, Issue 1, 2009, Pages 55-63

  Ali, Raisuddin ^a   Jain, Gaurav K ^a   Iqbal, Zeenat ^a   Talegaonkar, Sushma ^a   Pandit, Pragati ^c   Sule, Sunita ^c   Malhotra, Geena ^c   Khar, Roop K ^a   Bhatnagar, Aseem ^b   Ahmad, Farhan J ^a  

^a HAMDARD UNIVERSITY   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

^c CIPLA LTD   (India)

Author keywords

Atropine sulfate; Bulk characterization; Inhalation therapy; Nanoparticle; Organophosphorous poisoning; Precipitation method

Indexed keywords

ABSORPTION; BIOCHEMISTRY; BLOOD; ELECTRIC IMPEDANCE; NANOPARTICLES; PACKET NETWORKS; POWDERS; RESPIRATORY THERAPY; SOLVENTS; SUGARS;

ATROPINE SULFATE; BULK CHARACTERIZATION; INHALATION THERAPY; NANOPARTICLE; ORGANOPHOSPHOROUS POISONING; PRECIPITATION METHOD;

PRECIPITATION (CHEMICAL);

ATROPINE; LACTOSE; NANOPARTICLE; ORGANOPHOSPHORUS COMPOUND;

ADULT; ARTICLE; BLURRED VISION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DETERMINATION; DRUG EFFICACY; DRUG INDICATION; DRUG SYNTHESIS; DRY POWDER; EMERGENCY TREATMENT; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; INTESTINE; INTESTINE ABSORPTION; INTOXICATION; LUNG; MALE; METHODOLOGY; MYDRIASIS; NORMAL HUMAN; PARTICLE SIZE; POWDER INHALER; PRECIPITATION; SIDE EFFECT; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE; THIRST; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADULT; ATROPINE; CALORIMETRY, DIFFERENTIAL SCANNING; HUMANS; NANOMEDICINE; NANOPARTICLES; ORGANOPHOSPHORUS COMPOUNDS; PARTICLE SIZE; POISONING; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION; YOUNG ADULT;

EID: 59849083500     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2008.07.001     Document Type: Article

References (22)

1. Chapman W.P., Rowlands P., and Jones C.M. Antispasmodic drugs: evaluation of their effects on the motor activity of the upper portion of the small intestine in man. JAMA 143 (1950) 627-630
2. Kehe C.R., Lasseter K.C., Miller N.C., Wick K.A., Shamblen E.C., and Ekholm B.P. Comparative absorption of atropine from a metered dose inhaler and an intramuscular injection. Ther Drug Monitor 14 (1992) 132-134
3. Callahan J.C., Cleary G.W., and Elefant M. Equilibrium moisture content of pharmaceutical excipients. Drug Dev Ind Pharm 8 (1982) 355-369
4. Xu A., Havel J., Linderholm K., and Hulse J. Development and validation of an LC/MS/MS method for the determination of l-hyoscyamine in human plasma. J Pharm Biomed Anal 14 (1995) 33-42
5. Chow A.H.L., Tong H.H.Y., Chattopadhyay P., and Shekunov B.Y. Particle engineering for pulmonary delivery. Pharm Res 24 (2007) 411-437
6. Dollery C. Therapeutic drugs. 2nd ed. (1999), Churchill Livingstone, New York A240-A245
7. Podczeck F. The relationship between physical properties of lactose monohydrate and the aerodynamic behaviour of adhered drug particles. Int J Pharm 160 (1998) 119
8. Zeng X.M., Martin G.P., Tee S., Ghoush A.A., and Marriott C. Effect of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation. Int J Pharm 182 (1999) 133
9. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv 68 (2001) 27-42
10. Dateand A.A., and Patravale V.B. Current strategies for engineering drug nanoparticles. Curr Opin Colloid Interf 9 (2004) 222-235
11. Midoux N., Hosek P., Pailleres L., and Authelin J.R. Micronization of pharmaceutical substances in a spiral jet mill. Powder Technol 104 (1999) 113-120
12. Liversidge E.M., Liversidge G.G., and Cooper E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 18 (2003) 113-120
13. Krause K.P., and Muller R.H. Production and characterization of highly concentrated nanosuspensions by high pressure homogenization. Int J Pharm 214 (2001) 21-24
14. Reverchon E. Supercritical antisolvent precipitation of micro- and nanoparticles. J Supercrit Fluid 15 (1999) 1-21
15. 2 as antisolvent with enhanced mass transfer. Ind Eng Chem Res 40 (2001) 3530-3539
16. Charoenchaitrakool M., Dehghani F., and Foster N.R. Micronization by rapid expansion of supercritical solutions to enhance the dissolution rates of poorly water-soluble pharmaceuticals. Ind Eng Chem Res 39 (2000) 4794-4802
17. Pathak P., Meziani M.J., Desai T., and Sun Y. Nanosizing drug particles in supercritical fluid processing. J Am Chem Soc 126 (2004) 10842-10843
18. Rasenack N., Steckel H., and Muller B.W. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J Pharm Sci 92 (2003) 35-44
19. Mathiowitz E, Thanos C, Liu Z. Methods for micronization of hydrophobic drugs. United States Patent US6824791. August 26, 2004.
20. Rasenack N., Steckel H., and Muller B.W. Preparation of microcrystals by in situ micronization. Powder Technol 143-144 (2004) 291-296
21. Brittain H.G., and Fiese E.F. Effects of pharmaceutical processing on drug polymorphs and solvates. In: Brittain H.G. (Ed). Polymorphism in pharmaceutical solids (1999), Marcel Dekker, New York 332-358
22. Tong H.H.Y., and Chow A.H.L. Control of physical forms of drug particles for pulmonary delivery by spray drying and supercritical fluid processing. Chem Inform 21 (2007) 27-40